As regulatory expectations and scientific capabilities continue to evolve, preclinical drug development is entering a pivotal moment. Pressure to reduce animal use, improve human relevance, and accelerate timelines is reshaping how researchers evaluate efficacy and safety early in the pipeline. Rather than replacing one approach with another, leaders across the life sciences are embracing a more nuanced strategy—one rooted in integration, not elimination.
In a recent GEN Point of View article, Mike Garrett, CEO of Taconic Biosciences, outlines why the future of drug discovery depends on combining next‑generation new approach methodologies (NAMs) with advanced, fit‑for‑purpose in vivo models rather than treating them as opposing choices. His perspective reflects a growing consensus: progress happens fastest when scientific tools work together.
“The path forward lies in integration, not elimination” said Garrett in GEN.
Moving Beyond the Binary Debate in Preclinical Research
Recent FDA guidance has encouraged reduced reliance on traditional animal models. At the same time, breakthrough innovation in organoids, microphysiological systems, and computational modeling has transformed early discovery workflows.
However, positioning animal and non‑animal approaches as mutually exclusive creates a false choice. While NAMs are powerful, they are not designed to answer every translational question in isolation—particularly those involving systemic exposure, immune complexity, or long‑term safety.
As Garrett notes, many of the most critical development decisions still require fully integrated biological systems capable of modeling disease in context.
Redefining NAMs: Function Over Format
One of the most important shifts highlighted in the GEN article is how NAMs themselves are being redefined. Rather than focusing solely on whether a model is animal‑based or non‑animal, regulators and researchers are increasingly evaluating how effectively a system answers a specific scientific question.
This functional definition aligns closely with the 3Rs of animal research—replacement, reduction, and refinement—and creates broader space for innovation:
- Replacement when non‑animal systems can fully model biology
- Reduction when refined models decrease overall animal use
- Refinement when advanced in vivo systems improve translational value and welfare
Importantly, this framework allows highly refined in vivo models to align with NAM objectives when they demonstrably improve relevance or efficiency.
Why Integration Improves Translational Confidence
Drug development failures often stem from translational gaps between preclinical findings and patient outcomes. An integrated model strategy helps close these gaps by allowing each system to do what it does best.
Advanced genetically engineered models (GEMs) and humanized systems, when used strategically alongside in vitro and in silico approaches, can:
- Improve reproducibility across studies
- Reduce redundant or low‑value experiments
- Generate richer, more predictive datasets
- Support confident regulatory decision‑making
Rather than increasing complexity, this coordinated use of tools creates clarity—helping teams answer the right questions at the right stage.
Regulatory Alignment Through Flexible Evidence Packages
Regulators are not prescribing a single methodological path forward. Instead, modern guidance emphasizes risk‑proportionate, science‑based evidence grounded in biological relevance rather than rigid categories.
An integrated preclinical strategy supports this flexibility by enabling tailored evidence packages that combine:
- Human‑relevant non‑animal data
- Mechanistic insight from refined in vivo models
- Computational and predictive analytics
This approach allows sponsors to demonstrate safety and efficacy with data that is fit for purpose—without over‑reliance on any single modality.
From Ethical Responsibility to Scientific Advantage
Ethical research and scientific rigor are not competing priorities. In fact, integration strengthens both. By optimizing how and when models are used, researchers can improve patient relevance while honoring the intent of the 3Rs.
As Garrett writes, combining complementary technologies ultimately “offers the most credible route to safer, more successful therapies for patients.”
In practice, this means fewer late‑stage failures, better resource allocation, and faster delivery of therapies to those who need them.
Building the Future of Preclinical Drug Discovery
The momentum behind NAMs represents genuine progress—but eliminating proven biological systems altogether risks creating new blind spots. Integration, by contrast, reflects how science actually advances: through layered evidence, cross‑validation, and continuous refinement.
For organizations navigating the evolving preclinical landscape, the message is clear. Success will not come from choosing sides—but from designing intelligent, integrated workflows that balance innovation with biological realism.
Key Takeaways
